Yale tests common drug to rescue failing hearts and kidneys
NCT ID NCT07273838
Summary
This study is testing if adding a pill called an SGLT2 inhibitor (a type of diabetes drug) to standard hospital care is safe and helps patients who are hospitalized with both worsening heart failure and sudden kidney injury. Researchers will enroll 130 adults and randomly give them either the drug or a placebo (sugar pill) for up to 14 days. The main goal is to see if the drug helps patients recover better by improving heart and kidney outcomes together, reducing the need for dialysis, and helping them leave the hospital sooner.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Yale New Haven Hospital
RECRUITINGNew Haven, Connecticut, 06510, United States
Contact
-
Yale New Haven Hospital-St. Raphael Campus
RECRUITINGNew Haven, Connecticut, 06510, United States
Contact
Conditions
Explore the condition pages connected to this study.